Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
19.8M
-
Number of holders
-
30
-
Total 13F shares, excl. options
-
379K
-
Shares change
-
+379K
-
Total reported value, excl. options
-
$770K
-
Value change
-
+$770K
-
Number of buys
-
29
-
Price
-
$2.03
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q1 2025
30 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q1 2025.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 30 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 379K shares
of 19.8M outstanding shares and own 1.92% of the company stock.
Largest 10 shareholders include Murchinson Ltd. (136K shares), UBS Group AG (102K shares), GOLDMAN SACHS GROUP INC (24.8K shares), BlackRock, Inc. (23.2K shares), GEODE CAPITAL MANAGEMENT, LLC (22.1K shares), Beacon Pointe Advisors, LLC (18.8K shares), VANGUARD GROUP INC (18.8K shares), WELLS FARGO & COMPANY/MN (12.3K shares), Virtu Financial LLC (10.7K shares), and BARCLAYS PLC (1.91K shares).
This table shows the top 30 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.